Skip to content
    • Company OverviewTeamCareers
    • Our ApproachPublications & Presentations
    • Patients & FamiliesPatient Spotlight
    • OPGx-BEST1OPGx-LCA5
  • Investors
  • Contact Us
  • About Us
    • Company Overview
    • Team
    • Careers
  • Gene Therapies
    • Our Approach
    • Publications & Presentations
  • Patients
    • Patients & Families
    • Patient Spotlight
  • Pipeline & Programs
    • OPGx-BEST1
    • OPGx-LCA5
  • Investors
  • Contact Us

Publications & Presentations

Program
BEST1
LCA5
MERTK
NMNAT1
RDH12
RHO
Conference
ARVO
Proceedings of the NASUSA
Proceedings of the NAS
Retinal Degeneration Conference
AOS
CTS
APAO
Macula Society
AEMB
AJOCR
Molecular Therapy
Human Gene Therapy
Cold Spring Harbor Perspectives in Medicine
British Journal of Ophthalmology
Investigative Ophthalmology and Visual Science
Drug Design, Development and Therapy
Nature Genetics
American Journal of Pathology
Molecular Therapy: Methods and Clinical Development
Human Molecular Genetics
AARVO
ASGCT
Retinal Imaging Biomarkers & Endpoints Summit
RD International Symposium
Foundation Fighting Blindness Retinal Therapeutics Innovation Summit
  • LCA5

    ARVO

    May 2026

    Restoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5

    Lead Author: Aleman.
  • RHO

    ARVO

    May 2026

    Nonclinical Efficacy and Toxicity Study of GMP-Grade Vector OPGx-RHO (Scaav2/5-RHO820-Shrna820) Delivered by Subretinal Injection in a Canine Model of RHO-adRP

    Lead Author: Dufour.
  • LCA5

    ARVO

    May 2026

    Restoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5

    Lead Author: Aleman.
  • BEST1

    ARVO

    May 2026

    Development of Cell-Based Expression and Functional Potency Assays for OPGx-BEST1 Gene Therapy

    Lead Author: Siriwardena.
  • BEST1

    ARVO

    May 2026

    Preliminary Results from Adult Participant in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for ARB and BVMD Due to BEST1 Mutations

    Lead Author: Pennesi.
  • RHO

    ARVO

    April 2026

    Therapeutic Efficacy of a Mutation-Independent AAV Knockdown and Replacement Approach in a Swine Animal Model of Autosomal-Dominant Retinitis Pigmentosa (adRP)

    Lead Author: Jaligampala.
  • RHO

    Foundation Fighting Blindness Retinal Therapeutics Innovation Summit

    April 2026

    Safety and Efficacy of OPGx-RHO Silence-and-Replace Gene Therapy for RHO-adRP: Evidence Across Two Large Animal Models

    Lead Author: Jayagopal.
  • RHO

    ASGCT

    April 2026

    Nonclinical efficacy and toxicity study of GMP-grade vector OPGx-RHO (scAAV2/5-RHO820-shRNA820) delivered by subretinal injection in a canine model of RHO-adRP

    Lead Author: Choudhary.
  • BEST1

    Macula Society

    February 2026

    Preliminary Results from an Adult Participant in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for the Treatment of BVMD and ARB Due to BEST1Mutations

    Lead Author: Pennesi.
  • BEST1

    APAO

    February 2026

    Gene Therapy for BEST1 Inherited Retinal Disease

    Lead Author: Jayagopal.
  • LCA5

    RD International Symposium

    August 2025

    One Year Results from a Phase 1/2 Study of OPGx-LCA5 Subretinal Gene Therapy for the Treatment of LCA5-LCA in Adult Participants

    Lead Author: Jayagopal.
  • BEST1

    CTS

    June 2025

    Current and Emerging Endpoints for IRDs

    Lead Author: Jayagopal.
  • No publications found.

Sign up to receive our newsletter

Follow us

  • Gene Therapies
  • Patients & Families
  • Pipeline
  • About Us
  • Careers
  • Contact Us
  • Investors
© 2026 Opus Genetics, Inc.
  • Cookie Policy
  • Privacy Statement
Site by BKW